Stocks

Clovis Oncology halts mid-stage bladder cancer trial, shares drop

April 12 (Reuters) - Clovis Oncology Inc said on Friday it was halting a mid-stage trial testing its lead drug in bladder cancer patients, sending shares down 12 percent.

The company said its decision to discontinue the trial was based on recommendations of an independent committee, which suggested that the treatment may not provide a meaningful benefit to patients.

However, Clovis said it would continue to test the drug, Rubraca, in combination with other treatments for bladder cancer.

Rubraca belongs to a new class of cancer drugs called PARP-inhibitors, which work by blocking enzymes involved in repairing damaged DNA of cancer cells, thereby helping to kill them.

Shares of the Boulder, Colorado-based drug developer fell 12.5 percent to $20.55 after market hours.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CLVS

Other Topics

World Markets Technology

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More